Wells Fargo Upgrades Algonquin Power to Overweight, Announces $9 Price Target
Wells Fargo analyst Neil Kalton upgrades Algonquin Power (NYSE:AQN) from Equal-Weight to Overweight and announces $9 price target.
Jefferies Upgrades Check Point Software to Buy, Raises Price Target to $150
Jefferies analyst Joseph Gallo upgrades Check Point Software (NASDAQ:CHKP) from Hold to Buy and raises the price target from $135 to $150.
Jefferies Upgrades Atlassian to Buy, Announces $150 Price Target
Jefferies analyst Brent Thill upgrades Atlassian (NASDAQ:TEAM) from Hold to Buy and announces $150 price target.
Truist Securities Upgrades Silgan Hldgs to Buy, Announces $64 Price Target
Truist Securities analyst Michael Roxland upgrades Silgan Hldgs (NYSE:SLGN) from Hold to Buy and announces $64 price target.
Truist Securities Upgrades Comcast to Buy, Announces $50 Price Target
Truist Securities analyst Greg Miller upgrades Comcast (NASDAQ:CMCSA) from Hold to Buy and announces $50 price target.
Evercore ISI Group Upgrades Reinsurance Group to Outperform, Raises Price Target to $167
Evercore ISI Group analyst Thomas Gallagher upgrades Reinsurance Group (NYSE:RGA) from In-Line to Outperform and raises the price target from $148 to $167.
B of A Securities Upgrades Interpublic Gr of Cos to Neutral, Raises Price Target to $36
B of A Securities analyst Adrien de Saint Hilaire upgrades Interpublic Gr of Cos (NYSE:IPG) from Underperform to Neutral and raises the price target from $22 to $36.
Credit Suisse Upgrades Cboe Global Markets to Outperform, Lowers Price Target to $144
Credit Suisse analyst Gautam Sawant upgrades Cboe Global Markets (BATS:CBOE) from Neutral to Outperform and lowers the price target from $159 to $144.
Goldman Sachs’ Four Zones Within Capital Market Coverage, Gives Stock Picks
Goldman Sachs Group Inc (NYSE: GS) has outlined four themes for 2023 amid recessionary risks and rising interest rates.
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be a volatile 2023.